Research Article

Accuracy of Self-Reported Breast Cancer Information among Women from the Ontario Site of the Breast Cancer Family Registry

Table 3

Agreement analysis1 comparing information from self-administered questionnaires with medical record information in 939 women with breast cancer.

Proportion correct (%)
Sensitivity (%)Specificity (%)PPV (%)NPV (%)Kappa

Hormone therapy 92.693.295.095.792.20.88
Chemotherapy 93.697.296.692.496.60.88
Radiation treatment298.399.896.499.0099.50.97
Surgery99.099.799.7
Breast cancer recurrence94.875.597.360.798.60.65
Menopausal status395.60.89
Menopausal status483.00.71
Hormonal medication
 Tamoxifen89.991.180.997.354.80.60
 Megestrol97.931.2100.0100.097.90.47
 Anastrozole89.817.699.175.089.20.25
 MA1295.754.597.548.098.90.49
Chemotherapy medication
 Cyclophosphamide55.456.640.591.97.3−0.01
 Flurouracil60.255.279.891.531.10.22
 Methotrexate77.049.395.186.974.20.48
 Epirubicin82.454.797.492.078.90.57
 Doxorubicin 83.548.396.985.783.10.52
 Docetaxel89.46.799.880.089.50.11
Surgery
 Mastectomy99.896.299.596.598.30.95
 Lumpectomy93.499.197.591.997.50.84

1Agreement analysis was conducted excluding unknown and missing responses.
2Agreement analysis for radiation therapy was conducted excluding women with breast cancer recurrence (according to medical records).
3Calculated excluding unknown and missing information (i.e. treating menopausal status as a 2-level variable of premenopausal and postmenopausal).
4Calculated including unknown and missing information (i.e. treating menopausal status as a 3-level variable of premenopausal, postmenopausal, and unknown/missing. Unknown/missing information that match between medical records and treatment questionnaire data are treated as in agreement).